4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Pharming Group N.V. (PHAR) operates in the Biotechnology industry and is headquartered in Leiden, Netherlands with about 407 employees. Its market capitalization is roughly $992 million. In the fiscal year ended 2025-12-31, PHAR reported $376M in revenue and $3M in net income.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Interactive charts & full statements → Open the PHAR valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $376M | $297M | $245M | $206M | — |
| Gross Profit | $331M | $262M | $220M | $188M | — |
| Operating Income (EBIT) | $21M | ($4M) | ($22M) | $10M | — |
| Net Income | $3M | ($12M) | ($10M) | $14M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $72M | $106M | $97M | $93M | $79M | — |
| Gross Profit | $66M | $85M | $90M | $84M | $71M | — |
| Operating Income (EBIT) | ($5M) | $2M | $16M | $9M | ($7M) | — |
| Net Income | ($5M) | $5M | $8M | $5M | ($15M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | $0M | $0M | $0M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Dividends Paid | $0M | $0M | $0M | $0M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $500M | $400M | $463M | $426M | — |
| Total Liabilities | $223M | $179M | $244M | $221M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PHAR viewer.
About TickerBase · Data methodology & sources